Real-world Study for Patients With Advanced Hepatobiliary Tumors
Conditions
- Objective Response Rate
- Progression-free Survival
- Overall Survival
- Disease Control Rate
- Duration of Response
- Five-year Survival Rate
- Quality of Life
Interventions
- DRUG: Precision oncology including targeted therapy and immunotherapy
Sponsor
Peking Union Medical College Hospital
Collaborators